ClinicalTrials.gg
RecruitingNCT06911060Updated Oct 23, 2026

Flaxseed Consumption on Biochemical and Quality of Life in Type 2 Diabetes

An interventional study of Flaxseed and Diet in Type 2 Diabetes Mellitus (T2DM), sponsored by Ondokuz Mayıs University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.
Updated Oct 23, 2026Now RecruitingFirst site in Turkey (Türkiye)+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey — 61 open to participants now, 71 under way, 12 of them phase 3. Diabetes Mellitus, Type 2 · Turkey.

Planned enrollment
231st of 266
46 · median 100
Started
2025
with 25 others
No phase
150 of 342
33 open now
Primary completion
2027-05
later than 49 of 70 live
Registered
253rd of 342
by date

Among the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, this one is the 231st largest by planned enrollment of the 266 interventional ones that give a count, is one of 26 that started in 2025, is one of 150 with no phase, reaches primary completion later than 49 of the 70 other live ones, and was the 253rd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

61 of the 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey are open now. Recruiting first, the newest first:

56 more — sign in →

All 61 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 342 studies in Diabetes Mellitus, Type 2 with a site in Turkey, or all of them as a file.
02

Study summary

The main goal of this clinical trial is to determine the effect of flaxseed added to the diet on biochemical parameters and quality of life in patients with Type 2 diabetes mellitus (T2DM). The main questions it aims to answer are:

  • Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on biochemical parameters?
  • Does flaxseed supplementation given to T2DM patients for 12 weeks have an effect on quality of life?

Researchers will compare patients with T2DM consume diet added flaxseed to a control group to see if flaxseed effect on biochemical parameters and quality of life.

Participants will:

  • Complete the questionnaire, record the 3-day food consumption and be taken the anthropometric measurements at the beginning and end of the study.
  • Take diet added 30 g ground flaxseed (intervention group) or only diet (control group) every day for 12 weeks.
  • Visit the clinic once every 4 weeks for follow-up.
  • Report the dietary adherence and gastrointestinal symptoms on a phone call once every week.
Read the detailed description

Adult individuals between the ages of 19-65, with a body mass index (BMI) between 20-35 kg/m2, using oral anti-diabetics and not using insulin will be included in the study. Patients with T2DM who agree to participate in the study will be randomly assigned to the intervention or control group using the simple randomization method. Participants will be followed for 12 weeks. Both groups will receive diet as part of T2DM treatment. Subjects in the intervention group will consume 30 g of ground flaxseed per day in addition to their diet. The participants were asked by the researchers through a face-to-face interview technique to determine their demographic characteristics (age, marital status, education level, employment status, income level, etc.), quality of life short form (SF-36) scale, international physical activity questionnaire (IPAQ) and 3-day food consumption record. A survey form questioning consumption records will be applied at the baseline and end of the study. In addition, routinely monitored biochemical parameters of the patients will be recorded from the hospital system at the baseline and end of the study. Anthometric measurements will be taken and recorded by the researcher in accordance with the method. The data obtained will be evaluated in the SPSS package program.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)

Keywords

  • Type 2 diabetes mellitus
  • flaxseed
  • quality of life
  • glycemic control
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with T2DM by a physician
  • Being between the ages of 19-65
  • Having a (BMI) between 20-35 kg/m2
  • Using oral anti-diabetics and not using insulin

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal diseases
  • High consumption of nuts, flaxseeds or sesame seeds (more than one serving per day)
  • Food allergies or intolerances
  • Renal failure, liver, other endocrine or inflammatory disorders
  • Use of lipid-lowering drugs
  • Smoking and alcohol use
  • Being pregnant or lactating
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Diet+Flaxseed

    Diet will be planned to patients with T2DM as a part of their medical nutritional therapy. This group will take 30 g/d ground flaxseed within their diet.

    Dietary Supplement: Flaxseed · Behavioral: Diet

  • Experimental
    Diet

    Diet will be planned to patients with T2DM as a part of their medical nutritional therapy.

    Behavioral: Diet

Interventions

  • Dietary supplementFlaxseed

    30 g/day for 12 weeks

  • BehavioralDiet

    Diet will be planned to patients with T2DM as a part of their medical nutrition therapy.

06

What researchers measure

Primary outcomes

  1. Evaluation of the effect of flaxseed on fasting blood glucose (mg/dL)

    Time frame: From enrollment to the end of intervention at 12 weeks

  2. Evaluation of the effect of flaxseed on HbA1c (%)

    Time frame: From enrollment to the end of intervention at 12 weeks

  3. Evaluation of the effect of flaxseed on total triglyceride (mg/dL)

    Time frame: From enrollment to the end of intervention at 12 weeks

  4. Evaluation of the effect of flaxseed on total cholesterol (mg/dL)

    Time frame: From enrollment to the end of intervention at 12 weeks

  5. Evaluation of the effect of flaxseed on HDL-cholesterol (mg/dL)

    Time frame: From enrollment to the end of intervention at 12 weeks

  6. Evaluation of the effect of flaxseed on LDL-cholesterol (mg/dL)

    Time frame: From enrollment to the end of intervention at 12 weeks

  7. Evaluation of the effect of flaxseed on quality of life

    Quality of life will be assessed with SF-36. The total score is evaluated separately into two summary scores: the physical component summary (PCS12) and the mental component summary (MCS12). The score of the answers related to the PCS12 is obtained from the factors of general health, role-physical, physical functioning, and bodily pain, and the score of the answers related to the MCS12 is obtained from the factors of social functioning, role-emotional, mental health, and energy/fatigue. Both scores range from 0 to 100, with a higher score representing better health.

    Time frame: From enrollment to the end of intervention at 12 weeks

Secondary outcomes

  1. Evaluation of the effect of flaxseed on BMI (kg/m2)

    Time frame: From enrollment to the end of intervention at 12 weeks

  2. Evaluation of the effect of flaxseed on waist circumference (cm)

    Time frame: From enrollment to the end of intervention at 12 weeks

  3. Evaluation of the effect of flaxseed on waist/hip ratio

    Time frame: From enrollment to the end of intervention at 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Omü Suvam
    Samsun, Turkey (Türkiye)
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2027, 20 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Apr 2026 → May 2027 and completion May 2026 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2025
First posted
Apr 4, 2025
StartActual
Sep 30, 2025
Primary completionEst.
May 2027was Apr 2026
CompletionEst.
May 12, 2027was May 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added — first site in Turkey (Türkiye)
Show site
  • Omü Suvam · Samsun, Turkey (Türkiye)
Oct 23, 2026
Primary completion
Apr 2026→May 2027
Oct 23, 2026
Study completion
May 12, 2026→May 12, 2027
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Turkey (Türkiye)
    Show site
    • Omü Suvam · Samsun, Turkey (Türkiye)
    Primary completion Apr 2026→May 2027
    Study completion May 12, 2026→May 12, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06911060
Responsible party
YASEMİN ERTAŞ ÖZTÜRK (Assist. Prof., Ondokuz Mayıs University) — Principal investigator
First posted
Apr 4, 2025
Start date
Sep 30, 2025
Primary completion
May 2027 (estimated)
Completion
May 12, 2027 (estimated)
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Flaxseed

Start the discussion